U.S. Markets open in 7 hrs 18 mins

Rite Aid Corp (RAD) Files 10-K for the Fiscal Year Ended on February 28, 2017

- By insider

Rite Aid Corp (RAD) files its latest 10-K with SEC for the fiscal year ended on February 28, 2017. Rite Aid Corp operates retail drugstore chains in the United States. It operates approximately 4,561 stores in 31 states across the country and in the District of Columbia. Rite Aid Corp has a market cap of $4.16 billion; its shares were traded at around $4.06 with and P/S ratio of 0.13. Rite Aid Corp had annual average EBITDA growth of 7.70% over the past five years.


For the last quarter Rite Aid Corp reported a revenue of $8.5 billion, compared with the revenue of $8.3 billion during the same period a year ago. For the latest fiscal year the company reported a revenue of $32.8 billion, an increase of 6.9% from last year. For the last five years Rite Aid Corp had an average revenue growth rate of 5.2% a year.

The reported diluted earnings per share was 0.4 cents for the year, a decline of 97.5% from the previous year. The Rite Aid Corp had an operating margin of 1.62%, compared with the operating margin of 2.49% a year before. The 10-year historical median operating margin of Rite Aid Corp is 1.23%. The profitability rank of the company is 6 (out of 10).

At the end of the fiscal year, Rite Aid Corp has the cash and cash equivalents of $245.4 million, compared with $124.5 million in the previous year. The long term debt was $7.3 billion, compared with $7 billion in the previous year. The interest coverage to the debt is 1.2, which is not a favorable level. Rite Aid Corp has a financial strength rank of 5 (out of 10).

At the current stock price of $4.06, Rite Aid Corp is traded at 30.1% premium to its historical median P/S valuation band of $3.12. The P/S ratio of the stock is 0.13, while the historical median P/S ratio is 0.10. The stock lost 48.88% during the past 12 months.

For the complete 20-year historical financial data of RAD, click here.

This article first appeared on GuruFocus.